TILDELING AV FORSKNINGSMIDLER 2015 UNIVERSITETET I BERGEN Søker Prosjekttittel Institusjon Innvilget Beløp Rein Aasland The role of histone acetylation in enhancer function Universitetet i Bergen Thomas Arnesen Mathias Ziegler Human enzymes overexpressed in cancers - novel targets for cancer therapy Metabolic hub molecules as key factors in cancer development and prevention Universitetet i Bergen Universitetet i Bergen Rolf Bjerkvig Identifying molecular targets on human glioblastoma. (GBM-TARGET) Universitetet i Bergen Frits Thorsen Finding new uses for old drugs in clinical treatment of brain metastases Universitetet i Bergen Generelle driftsmidler 225 000 Forskerstipend, 1-4. år 3 923 836 Generelle driftsmidler 500 000 Generelle driftsmidler 200 000 Generelle driftsmidler 300 000 Generelle driftsmidler 419 000 Martha Chekenya Natural Killer cellular therapy for Glioblastoma:Role of KIR2DS4+NKG2C+ NK subsets in immunosurveillance and progression Universitetet i Bergen Generelle driftsmidler 200 000 Per Enger Validating xct as a therapeutic target in human cancers Universitetet i Bergen Generelle driftsmidler 175 000 Øystein Bruserud NY FARMAKOLOGISK TERAPI VED AKUTT MYELOGEN LEUKEMI Universitetet i Bergen Emmet Mc Cormack Translational Development of Preclinical Models and Therapies in Myeloid Neoplasia Universitetet i Bergen Generelle driftsmidler 300 000
Bjørn Tore Gjertsen Xiang Wang Pre-apoptotic molecular mechanisms in acute myeloid leukemia Microfluidic device for rapid collection and phenotyping of circulating tumor cells Universitetet i Bergen Generelle driftsmidler 500 000 Universitetet i Bergen Kvalifiseringsstipend (3 år) 2 816 902 Stein Døskeland Terapi-relevant cancercelle døds-signalering Universitetet i Bergen Generelle driftsmidler 175 000 Per Lønning Genforandringer som årsak til behandlingsresistens samt betydning av hormonelle faktorer for utvikling av brystkreft Universitetet i Bergen Generelle driftsmidler 800 000 Stian Knappskog Genetic alterations affecting response to breast cancer therapy Universitetet i Bergen Lars A Akslen Biomarkers of Breast Cancer Heterogeneity Based on Tumor-Microenvironment Interactions Universitetet i Bergen Helga Salvesen Individualized therapy based on molecular alterations in gynecologic cancer Universitetet i Bergen Generelle driftsmidler 650 000 Halfdan Sørbye Treatment and markers of elderly metastatic colorectal cancer patients Haukeland universitets sykehus HF Klinisk korttidsstipend 942 000 Kari Dyregrov «The cancer changed my life»: - A mixed-method study of young adult cancer survivors challenges and psychosocial needs Senter for krisepsykologi
TILDELING AV FORSKNINGSMIDLER 2015 NTNU, HØGSKOLEN I SØR-TRØNDELAG OG ST. OLAVS HOSPITAL Søker Prosjekttittel Institusjon Innvilget Beløp Bjørn H. Grønberg Nordic Randomized Phase II Trial Comparing High-Dose With Standard-Dose Thoracic Radiotherapy In Limited Disease Small-Cell Lung Cancer NTNU Teknisk stilling (3 år) 1 109 943 Generelle driftsmidler 200 000 Lene Grøvdal Moving Tolls- How trafficking of TLRs regulate cancer NTNU Kvalifiseringsstipend (3 år) 2 816 902 Bodil Merete Kavli Role of activation-induced cytidine deaminase (AID) in development of B-cell lymphomas NTNU Generelle driftsmidler 140 000 Therese Standal Interleukin-32 in multiple myeloma NTNU Generelle driftsmidler 175 000 Kristian Starheim Targeting the RIP1 cell death pathway in tumor-associated macrophages as cancer therapy NTNU Kvalifiseringsstipend (3 år) 2 816 902 Anders Sundan Classification of multiple myeloma NTNU Anders Waage Clinical and Translational Research on Multiple Myeloma and Chronic myeloid leukemia NTNU
Geir Slupphaug Identification of novel biomarkers in B-cell lymphomas by quantitative mass spectrometry NTNU Generelle driftsmidler 175 000 Xiao-Mei Mai Genetic and causal association of vitamin D with lung cancer incidence in a Norwegian population NTNU Generelle driftsmidler 100 000 Lars Vatten Early life factors and breast cancer risk, by molecular subtypes NTNU Gjesteforskerstipend 914 000 Guro Giskeødegård Metabolomics for improved stratification of breast cancer patients based on prognosis and treatment response NTNU Kvalifiseringsstipend (3 år) 2 816 902 Siver Moestue USPIO MRI in prostate cancer: vascular imaging and lymph node staging NTNU Frank Skorpen Exploration of the potential utility of liquid biopsiesin improving outcomes of curative treatment of non-small-cell lung cancer (NSCLC) NTNU Generelle driftsmidler 200 000 Geir Bjørkøy Targeting Autophagy to interfere with tumor growth and cachexia Høgskolen i Sør-Trøndelag Generelle driftsmidler 175 000 Torgeir Wethal Acute and long-term cardiovascular toxicity after modern radiotherapy for breast cancer a prospective longitudinal study St. Olavs hospital HF Generelle driftsmidler 175 000 Torgrim Tandstad The SWENOTECA ABC-study St. Olavs hospital HF Generelle driftsmidler 100 000
TILDELING AV FORSKNINGSMIDLER 2015 UNIVERSITETET I TROMSØ Søker Prosjekttittel Institusjon Innvilget Beløp Lorena Arranz Neuroglial Regulation of the Haematopoietic Stem Cell Niche in Acute Myeloid Leukaemia Transformation Universitetet i Tromsø Generelle driftsmidler 800 000 Tom Dønnem Terje Johansen Clinical Implementation of TNM-Immunoscore in Resected Non-Small Cell Lung Cancer Roles of p62/sqstm1 and LIR-containing proteins in selective autophagy and cell signalling Universitetet i Tromsø Universitetet i Tromsø Generelle driftsmidler 700 000
TILDELING AV FORSKNINGSMIDLER 2015 UNIVERSITETET I OSLO Søker Prosjekttittel Institusjon Innvilget Beløp Heidi Blomhoff Erwan Delbarre Regulation of proliferation and cell death by camp and vitamin A in cells of the immune system ipscs to elucidate epigenetic processes underlying pediatric gliomas linked to mutations in a histone gene Universitetet i Oslo Universitetet i Oslo Anne Simonsen The role of selective autophagy in tumor suppression Universitetet i Oslo Anne Spurkland Evaluation of TSAd as a target for cancer therapy Universitetet i Oslo Generelle driftsmidler 250 000 Kvalifiseringsstipend (3 år) 2 816 902 Generelle driftsmidler 360 000 Generelle driftsmidler 500 000 Jason Matthews ADP-ribosylation regulates estrogen receptor signalling and breast cancer risk Universitetet i Oslo Generelle driftsmidler 175 000 Rune Blomhoff Diet, inflammation and oxidative stress in colorectal cancer patients: Preclinical and clinical studies Universitetet i Oslo Generelle driftsmidler 175 000 Marit Veierød Melanomas differ: Better understand to better prevent Universitetet i Oslo Generelle driftsmidler 120 000 Thomas Küntziger AKAP95 in chromosomal instability and cancer gene bookmarking Universitetet i Oslo Generelle driftsmidler 175 000 Ståle Petter Lyngstadaas Understanding the radiation biology of reconstructed bone Universitetet i Oslo Generelle driftsmidler 175 000 Michael Bretthauer Colorectal cancer screening and surveillance Universitetet i Oslo Forskerstipend, 1-4. år 3 923 836
Bjørn Dalhus Development of DNA base excision repair inhibitors as cancer therapy adjuvants Universitetet i Oslo Generelle driftsmidler 175 000 Ludvig A Munthe Pathogenesis and treatment of B cell Cancers Universitetet i Oslo Ragnhild Eskeland Chromatin organisation in cancer Universitetet i Oslo Generelle driftsmidler 175 000 Pål Øystein Falnes Functional studies of cancer relevant methylases, demethylases, and hydroxylases Universitetet i Oslo Generelle driftsmidler 500 000 Gareth Griffiths Development of nanoparticle drug and sirna therapy against cancer in cells and zebrafish Universitetet i Oslo Generelle driftsmidler 175 000 Fahri Saatcioglu Androgen action and prostate cancer - Development of markers and therapeutic targets Universitetet i Oslo Generelle driftsmidler 450 000 Yang Jin STAMPs as biomarkers in breast cancer Universitetet i Oslo Kvalifiseringsstipend (3 år) 2 816 902 Cinzia Progida Novel roles of Rab proteins in cell migration Universitetet i Oslo Generelle driftsmidler 200 000 Michael Leitges Analysis the relevance of the PKC/PKD signaling axis during tumorigenesis Universitetet i Oslo Generelle driftsmidler 500 000 Per Ottar Seglen CYTOPHAGY Universitetet i Oslo Generelle driftsmidler 175 000 Kjetil Taskén Molekylære mekanismer for camp-mediert regulering av celleproliferasjon og immunfunksjon Universitetet i Oslo Generelle driftsmidler 300 000
TILDELING AV FORSKNINGSMIDLER 2015 OSLO UNIVERSITETSSYKEHUS OG AKERSHUS UNIVERSITETSSYKEHUS Søker Prosjekttittel Institusjon Innvilget Beløp Magnar Bjørås Molykære mekansimer for DNA reparasjon Arne Klungland Characterization of novel and known DNA modifications in cancer initiation and progression Generelle driftsmidler 450 000 Bjarne Bogen T celler i immunovervåkning og immunterapi av kreft Generelle driftsmidler 175 000 Jorrit Enserink PRECISION MEDICINE FOR ACUTE MYELOID LEUKEMIA PATIENTS Alexandre Corthay Cancer immunotherapy by targeting tumor-infiltrating macrophages Generelle driftsmidler 169 000 Ole Audun Werner Haabeth Stig Ove Bøe Immunotherapeutic modulation of the bone marrow microenvironment in multiple myeloma Acute promyelocytic leukemia: molecular pathogenesis and mechanism of cure Kvalifiseringsstipend (3 år) 2 816 902 Generelle driftsmidler 175 000 Ingrun Alseth RNA modifications in cancer; the role of Endonuclease V Generelle driftsmidler 200 000 Kyrre Emblem TREATMENT - Improved Therapy Response Assessment in Metastatic Brain Tumors Eirik Malinen Image-based targeting of cancer
Cecilie Kiserud Alexander Fosså Hodgkin`s lymphoma: Risk and prevalence of long-term adverse effects and challenges for the health care service Euronet-PHL-C2 studien-en europeisk randomisert studie for optimalisert behandling av barn og unge med klassisk Hodgkin lymfom Generelle driftsmidler 175 000 Odd Terje Brustugun Precision oncology in lung cancer Generelle driftsmidler 175 000 Odd Terje Brustugun Novel EGFR-targeting therapy in non-small cell lung cancer. Treatment effects and resistance mechanisms. Klinisk korttidsstipend 942 000 Åslaug Helland Why are some cancers more aggressive? Generelle driftsmidler 175 000 Torgeir Bruun Wyller Kjersti Bruheim Treatment and survival in Norwegian cancer patients beyond 75 years of age Is the new concept of patient tailored radiotherapy safe in small cervical tumours? Klinisk korttidsstipend 942 000 Stein Andersson Executive functioning in survivors of pediatric brain tumors Generelle driftsmidler 100 000 Harald Stenmark Cell division and cancer Generelle driftsmidler 800 000 Camilla Raiborg ER-Endosome Contact: Implications for Tumour Suppressor Pathways, Cell Migration and Invasion Kaisa Haglund Cytokinesis and carcinogenesis Forskerstipend, 1-4. år 3 923 835 Generelle driftsmidler 100 000 Kay Oliver Schink Macropinocytosis in cancer cells - Culprit or Saviour? Kvalifiseringsstipend (3 år) 2 816 902 Sebastian Schultz Final steps of autophagosome closure - mechanistic insights and potential role in cancer Kvalifiseringsstipend (3 år) 2 816 902 Kirsten Sandvig Endocytosis and intracellular sorting of protein toxins
Alicia Llorente Sascha Pust Antoni Wiedlocha Extracellular Vesicles and Prostate Cancer: In Search of Tumorigenesis Mechanisms and Biomarkers Membrane crosslinkers in carcinogenesis: New possibilities for cancer diagnosis and therapy Next generation targeted radionuclide therapy for FGF receptor expressing cancers Generelle driftsmidler 175 000 Kvalifiseringsstipend (3 år) 2 816 902 Generelle driftsmidler 175 000 Jørgen Wesche Novel regulators of cancer cell migration Generelle driftsmidler 130 000 Ellen Margrethe Haugsten Ragnhild Lothe Switching off Met signalling - Identification of novel regulators and their relevance in metastatic prostate cancer Kreft, et resultat av genetiske og epigenetiske endringer. Modeller og mekanismer. Kvalifiseringsstipend (3 år) 2 816 902 Generelle driftsmidler 200 000 Guro Elisabeth Lind Epigenetic biomarkers for early detection and monitoring of cancer Generelle driftsmidler 175 000 Rolf Skotheim Kvalitativ transkriptvariasjon i kreft Heidi Lyng Molecular biomarkers in radiotherapy of cancer Anette Weyergang AN IMMUNE-MEDIATED GATEWAY FOR ELIMINATION OF CANCER Kvalifiseringsstipend (3 år) 2 816 902 Generelle driftsmidler 200 000 Einar Rofstad Tumor-Radiobiologi Generelle driftsmidler 175 000 Kristian Berg Fotokjemisk internalisering Generelle driftsmidler 175 000 Randi Syljuåsen DNA damage checkpoint signaling, hypoxia and radiation Generelle driftsmidler 175 000 Kristin Taskén Targeting therapy resistance in prostate cancer Generelle driftsmidler 175 000
Leonardo A Meza Zepeda Genome-wide genetic and epigenetic programs in cancer Generelle driftsmidler 175 000 Ola Myklebost Mesenchymal Cancer Medicine Generelle driftsmidler 800 000 Gunhild Mælandsmo Kjetil Boye Therapeutic approaches and molecular understanding of metastatic cancer Circulating tumor DNA as a biomarker in gastrointestinal stromal tumor Generelle driftsmidler 175 000 Kjersti Flatmark Colorectal cancer metastasis - a question of location Generelle driftsmidler 200 000 Øystein Fodstad Tumor-og molekylærbiologiske studier av metastaser. Utvikling av nye diagnostiske og terapeutiske metoder Generelle driftsmidler 175 000 Trevor Clancy Systems immunology to guide personalized cancer medicine Kvalifiseringsstipend (3 år) 2 816 902 Erlend Bremertun Smeland Kanutte Huse Biology of B cell lymphoma - identification of new diagnostic markers and targets for therapeutic intervention Deep profiling of tumor-cell heterogeneity and tumor-associated T cells in follicular lymphoma Kvalifiseringsstipend (3 år) 2 816 902 Johanna Olweus Genetically engineered T cells targeting cancer stem cells Generelle driftsmidler 600 000 Arne Kolstad Development of novel immunotherapies in malignant lymphoma - discovery of targets and T cell receptors Forskerstipend, 1-4. år 2 011 919 Karl-Johan Malmberg Development of Cell Therapies for Malignant Lymphomas Based on New Insights Into Natural Killer Cell Repertoire Diversity Generelle driftsmidler 385 000 Mouldy Sioud Sébastien Wälchli Improving Dendritic Cell Cancer Vaccine and Antibody Therapy: From Bench to Bedside DEVELOPMENT OF NOVEL STRATEGIES IN CANCER IMMUNOTHERAPY Generelle driftsmidler 175 000
June Myklebust Deciphering impact of genetic and proteomic alternations on drug sensitivity in B-cell lymphoma Generelle driftsmidler 350 000 Harald Holte Novel clinical and translational aspects of malignant B-cell lymphomas Forskerstipend, 1-4. år 2 011 919 Anders Tveita Immunotherapeutic targeting of tumor-associated macrophages Generelle driftsmidler 200 000 Hege Elisabeth Giercksky Russnes Intra tumor heterogeneity; from single cell analysis to diagnostic tools. Therese Sørlie Molecular portraits of breast cancer: Translating genomics to the clinical practice Generelle driftsmidler 175 000 Bjørn Naume Targeting occult tumor cell dissemination in localized breast cancer Vessela Kristensen The genetic Make-up and metabolic profile of breast cancer patients; relation to clinical course and treatment response Generelle driftsmidler 650 000 Kathrine Røe Redalen BioPicture - Biologic mapping for treatment individualisation in rectal cancer by functional magnetic resonance Akershus universitetssykehus HF Kvalifiseringsstipend (3 år) 2 816 902 Anne Ree Efficacy and Tolerability to Targeted Combined-Modality Therapy -- Biological Mechanisms in Colorectal Cancer Akershus universitetssykehus HF Anne Eskild Are women getting older at last menstrual period, and what may be causes and consequences of high age at menopause? Akershus universitetssykehus HF Hilde Nilsen Functional implications of the RNA- and DNA-processing activity of SMUG1 in telomere maintenance, stem cells, and cancer Akershus universitetssykehus HF Generelle driftsmidler 700 000 Hoa Thi Tuyet Tran Acute myeloid leukemia in the elderly Akershus universitetssykehus HF Klinisk korttidsstipend 942 000